1.72
-0.02 (-1.15%)
| Penutupan Terdahulu | 1.74 |
| Jumlah Dagangan | 146,092 |
| Harga / Buku (P/B) | 0.230 |
| Julat 52 Minggu |
| EPS Cair (TTM) | 476.10 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.42% |
| Nisbah Semasa (MRQ) | 2.72 |
| Aliran Tunai Operasi (OCF TTM) | -11.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -9.84 M |
| Pulangan Atas Aset (ROA TTM) | -12.83% |
| Pulangan Atas Ekuiti (ROE TTM) | -12.40% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Purple Biotech Ltd. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 2.50 |
|
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Institusi | 1.94% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |